To determine the prognostic factors related to recurrence and survival, and to evaluate the need for adjuvant chemotherapy in patients with endometrioid type epithelial ovarian cancer (EEOC).

This study included 63 EEOC patients who were surgically staged.

The FIGO 2014 stage was stage I in 41 (65%) patients, stage II in 8 (12.5%) patients, stage III in 14 (22.5%) patients. 5-year failure-free survival (FFS) was 78% in the entire cohort. 15 (23.8%) patients had disease failure. In univariate analysis, advanced stage (II&III), high grade tumor, presence of ascites, bilateral tumor, presence of omental metastasis, positive peritoneal cytology were prognostic factors for poor FFS. Only the stage was determined to be an independent prognostic factor for disease-failure. According to multivariate analysis, stage II&III was related to a statistically significant hazard ratio for a disease failure of 3.49 (95% confidence interval: 1.029-11.841; p = 0.045). The effectiveness of adjuvant chemotherapy was assessed for 41 patients with stage I. Eleven (26.8%) patients with stage I did not receive adjuvant chemotherapy. Whereas 5-year FFS was 88% in patients receiving adjuvant chemotherapy, that was 91% in patients without adjuvant chemotherapy (p =  0.923).

The independent prognostic factor for recurrence in EEOC was stage only. Adjuvant chemotherapy was not related to improvement in FFS in the early stage EEOC that were completely staged.